85.05
Ani Pharmaceuticals Inc stock is traded at $85.05, with a volume of 362.50K.
It is down -1.14% in the last 24 hours and up +4.86% over the past month.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
See More
Previous Close:
$86.03
Open:
$85.29
24h Volume:
362.50K
Relative Volume:
1.03
Market Cap:
$1.93B
Revenue:
$923.71M
Net Income/Loss:
$84.68M
P/E Ratio:
21.58
EPS:
3.9419
Net Cash Flow:
$182.81M
1W Performance:
+1.11%
1M Performance:
+4.86%
6M Performance:
+9.77%
1Y Performance:
+30.28%
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(609) 759-1810
Address
104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN
Compare ANIP vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ANIP
Ani Pharmaceuticals Inc
|
85.05 | 1.88B | 923.71M | 84.68M | 182.81M | 3.9419 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.89 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
9.72 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.29 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
75.42 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
547.25 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | H.C. Wainwright | Buy |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Mar-12-25 | Initiated | JP Morgan | Overweight |
| Dec-11-24 | Initiated | Leerink Partners | Outperform |
| Oct-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-15-24 | Initiated | CapitalOne | Overweight |
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
Insider Sell: Stephen Carey Sells Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus
ANI Pharmaceuticals (ANIP) CFO Stephen Carey sells 2,850 shares under Rule 10b5-1 plan - Stock Titan
ANI Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ANIP) - TradingView
ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple (NASDAQ:ANIP) - Seeking Alpha
ANIP Forecast — Price Target — Prediction for 2027 - TradingView
ANI Pharmaceuticals, Inc. Actuals & Estimates (BOATS:ANIP) - TradingView
ANI Pharmaceuticals (ANIP) Stock Could Be 29.5% Below Fair Value After Recent Pullback - Sahm
ANI Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $114.17, Implies 44% Upside - TradingView
ANI Pharmaceuticals Inc (ANIP) Valuation: PE, PB & Fair Value Analysis - TradingKey
ANI Pharmaceuticals Inc (ANIP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ANI Pharmaceuticals Inc (ANIP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ANI Pharmaceuticals Inc (ANIP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ANI Pharmaceuticals Inc (ANIP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ANI Pharmaceuticals Inc (ANIP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ANI Pharmaceuticals Inc (ANIP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ANI Pharmaceuticals Inc (ANIP) Institutional Confidence - TradingKey
ANI Pharmaceuticals Inc (ANIP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Insider Sell: Meredith Cook Sells 500 Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus
Ani Pharmaceuticals Sr. VP Cook sells $41,015 in stock - Investing.com UK
Ani Pharmaceuticals Sr. VP Cook sells $41,015 in stock By Investing.com - Investing.com Nigeria
ANI Pharmaceuticals (ANIP) VP sells 500 shares under 10b5-1 plan - Stock Titan
ANI Pharmaceuticals (ANIP) Stock Valuation After Recent Momentum And Cortrophin Growth Prospects - Sahm
Insider Sell: Thomas Haughey Sells 2,000 Shares of ANI Pharmaceu - GuruFocus
Ani Pharmaceuticals director Thomas Haughey sells $161,760 in stock - Investing.com
Ani Pharmaceuticals director Thomas Haughey sells $161,760 in stock By Investing.com - Investing.com India
ANI Pharmaceuticals (ANIP) director awarded 4,357 restricted shares vesting in 2027 - Stock Titan
ANI Pharmaceuticals (ANIP) director receives 4,357-share restricted stock award - Stock Titan
ANI Pharmaceuticals (ANIP) director sells 2,000 shares under plan - Stock Titan
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings? - Yahoo Finance
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push - Yahoo Finance
ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth - Yahoo Finance
CenterBook Partners LP Purchases Shares of 19,226 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $264,960 in stock - Investing.com UK
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $264,960 in stock By Investing.com - Investing.com South Africa
[Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
[144] ANI PHARMACEUTICALS INC SEC Filing - Stock Titan
ANI Pharmaceuticals, Inc. $ANIP Stock Holdings Trimmed by Global Alpha Capital Management Ltd. - MarketBeat
ANIP (NASDAQ: ANIP) broker files Form 144 for 11,862-share sale - Stock Titan
How ANI’s Estradiol Gel Recall at ANI Pharmaceuticals (ANIP) Has Changed Its Quality-Control Investment Story - Yahoo Finance
ANI Pharmaceuticals (ANIP) Jefferies Global Healthcare Conference 2026 Summary - Quartr
ANI Pharmaceuticals Revenue Grows 20 Percent in Q1 2026 Financial Results - asatunews.co.id
ANIP Stock Price, Quote & Chart | ANI PHARMACEUTICALS INC (NASDAQ:ANIP) - ChartMill
ANI Pharmaceuticals Inc (ANIP) Stock Down 3.2% -- Now Undervalued? GF Score: 77/100 - GuruFocus
Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term - Yahoo Finance
ANI Pharmaceuticals raises 2026 revenue outlook to $1.08B-$1.14B while launching $100M share repurchase program - MSN
ANI Pharmaceuticals (ANIP) Edges Higher: Approaching Key Resistance LevelsWeak Sell Signals - The Legal Advocate
ANI Pharmaceuticals (ANIP) expected to beat earnings estimates: Should you buy? - MSN
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ani Pharmaceuticals Inc Stock (ANIP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. |
Jun 12 '26 |
Sale |
82.03 |
500 |
41,015 |
77,890 |
| HAUGHEY THOMAS | Director |
Jun 08 '26 |
Sale |
80.88 |
2,000 |
161,760 |
38,878 |
| CAREY STEPHEN P. | SVP & CFO |
Jun 05 '26 |
Option Exercise |
49.51 |
3,312 |
163,977 |
183,705 |
| CAREY STEPHEN P. | SVP & CFO |
Jun 05 '26 |
Sale |
80.00 |
3,312 |
264,960 |
180,393 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):